Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.

Related Keywords

United States ,Eugenej Teoh ,Davide Gauden , ,National Comprehensive Cancer Network ,Clinical Practice Guidelines ,Blue Earth Diagnostics ,Blue Earth ,Earth Diagnostics ,Prostate Cancer ,